Editorial note: this article summarises published research and regulatory guidance on BPC-157, TB-500, LL-37 and KPV. Baclabs does not sell BPC-157, TB-500, LL-37, KPV or any peptide; we supply bacteriostatic water and reconstitution consumables. Nothing here is medical advice.
People who search “research peptides buy” are usually trying to answer two questions: is it legal, and how do I know what is in the vial. This article deals with both for the tissue-repair peptides covered in the regenerative peptides hub, BPC-157, TB-500, LL-37 and KPV. It explains what the “research use only” label means in UK law, how to read a certificate of analysis, and what “sterile vials for injection” requires of the vial, the powder and the diluent. It does not recommend suppliers, because none of these compounds is a licensed product.
Research peptides buy: what the label means
“Research peptides” are synthetic peptides sold as lyophilised (freeze-dried) powder in glass vials, labelled “for research purposes only”. Genuine laboratory reagents exist and are sold to institutions with accounts and safety data sheets. The retail market is different: consumer websites, card payments, 5 mg and 10 mg vials sized for personal use, and product pages that discuss healing and dosing. The label is a legal posture, not a description of the customer.
UK legal position
Regulation 46 of the Human Medicines Regulations 2012 states that “a person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product” [1]. Whether a peptide vial is a medicinal product depends on how it is presented (as treating or preventing disease) or on whether it modifies physiological function by pharmacological action. In April 2026 the MHRA told The Pharmacist that it disregards claims that products are “for research purposes” where it is clear those claims are being used to avoid medicines regulation, that it acts where promotional material shows a product is an unauthorised medicine intended for human use, and that it was reviewing a number of peptide websites for enforcement [2].
Buying a vial for personal use is not itself an offence. Selling one is, if the product is a medicinal product under the Regulations, regardless of the label. And an unlicensed product carries no quality protection: no marketing authorisation, no batch release by a Qualified Person, no pharmacovigilance. Other regulators have acted on the same basis; in April 2025 Health Canada warned that unauthorised injectable BPC-157, TB-500 and PT-141 from one seller could cause infection, allergic reactions and contain unlisted contaminants [3].
US regulation and why it matters here
On 29 September 2023 the FDA moved BPC-157, thymosin beta-4 fragment (TB-500), cathelicidin LL-37, KPV and 15 other peptides to Category 2 of its interim 503A bulk drug substances list, the category for substances that “raise significant safety risks”, removing them from pharmacy compounding [4][5]. The FDA’s stated reasons for BPC-157 included immunogenicity risk “for certain routes of administration” and “complexities with regard to peptide-related impurities and active pharmaceutical ingredient characterization” [5], and its 2026 briefing document added that immunogenicity may be amplified by aggregation and peptide-related impurities [9].
On 23 July 2026 the Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend adding BPC-157, KPV and TB-500 to the compounding list, against the unanimous advice of FDA scientists [6]. The vote is non-binding, requires rulemaking, and would only cover licensed compounding pharmacies working from characterised material. It does not change the status of retail vials.
How to read a certificate of analysis
A certificate of analysis (CoA) is the only evidence a buyer has about what is in the vial. Most are supplied by the vendor or a laboratory the vendor chose, so the first question is who ran the test. After that, three measurements matter.
HPLC purity
High-performance liquid chromatography separates the target peptide from everything else that absorbs ultraviolet light at the chosen wavelength, usually 214 or 220 nm. “Purity” on a CoA is the area of the main peak as a percentage of the total peak area. It does not tell you what the other peaks are (deletion sequences, truncated chains, oxidised residues, all potentially immunogenic) or how much of the vial’s mass is peptide at all.
Mass spectrometry
Mass spectrometry confirms identity. It reports the observed molecular mass of the main peak, which should match the calculated mass of the intended sequence to within a fraction of a dalton. A CoA with HPLC but no mass spectrum tells you the powder is pure without telling you what it is pure. For a tripeptide like KPV a mass alone is weak evidence; for BPC-157 or LL-37 it is more discriminating.
Endotoxin
Endotoxins are lipopolysaccharide fragments from gram-negative bacterial cell walls. They survive filtration and autoclaving and cause fever and inflammation when injected. The pharmacopoeial test is USP <85>, the Bacterial Endotoxins Test, using Limulus amoebocyte lysate (LAL) in gel-clot or photometric (turbidimetric and chromogenic) formats, with the gel-clot method as the compendial referee in a dispute [7]. The FDA’s limit for parenteral drugs is calculated as K/M, where K is 5.0 EU/kg, the approximate threshold pyrogen dose in humans, and M is the maximum dose per kilogram per hour [8]. A CoA with no endotoxin result has not tested for the contaminant most likely to cause an acute reaction to an injected peptide.
What a CoA usually leaves out
Net peptide content (lyophilised peptides carry bound water and counter-ions, often trifluoroacetate, typically 10–30% of the mass, so a “5 mg” vial at 99% purity may hold 3.5–4.5 mg of peptide); sterility, which no chemistry test addresses; and a batch number that matches the vial. A CoA without a batch number is marketing.
| Test | What it tells you | What it does not tell you |
|---|---|---|
| HPLC purity | Main peak as % of peptide-like material | Identity; nature of impurities; net peptide mass |
| Mass spectrometry | Molecular mass matches intended sequence | Purity; sterility; endotoxin |
| Endotoxin (USP <85> LAL) | Pyrogen burden in EU/mg or EU/vial | Chemical identity or purity |
| Net peptide content | Actual peptide mass versus label | Usually omitted from retail CoAs |
| Sterility test | Absence of viable microbes | Almost never performed for retail vials |
Sterile vials for injection: what the term requires
A licensed injectable is filled in an aseptic facility into depyrogenated glass vials and released only after sterility and endotoxin testing on the batch. Retail peptide vials are filled from bulk powder, and the sterility of the fill is asserted rather than demonstrated. The vial itself, a small glass vial with rubber stopper and aluminium crimp, is the least of the problem; the contents and the diluent determine whether the solution is fit for injection.
Three components have to be sterile: the powder, the diluent, and everything that touches them. Of the three, the diluent is the one a buyer can actually control, because bacteriostatic water and sterile water for injection are manufactured to pharmacopoeial standards with sterility and endotoxin release testing. A pharmaceutical-grade diluent does not sterilise a peptide of unknown sterility; it does mean the diluent is not adding to the problem, and a preserved diluent limits growth of anything introduced during repeated draws. The choice between preserved and unpreserved water is explained in bacteriostatic vs sterile water.
Reconstitution supplies
Peptide vials are multi-dose: a 5 mg vial reconstituted with 2 mL gives 2,500 mcg/mL, drawn down over weeks, and each puncture is an opportunity for contamination. Baclabs supplies UK-stocked bacteriostatic water (0.9% benzyl alcohol, 30 mL vials) for exactly that use; the reconstitution guide covers the maths and technique, and storage and shelf life explains the 28-day limit after first puncture. Worked examples are in the BPC-157 protocol guide and the Wolverine stack article.
Frequently asked questions
Is it legal to buy research peptides in the UK?
Possessing an unlicensed peptide for personal use is not an offence. Selling or supplying one that meets the definition of a medicinal product breaches regulation 46 of the Human Medicines Regulations 2012, and the MHRA has said “research purposes” labelling does not change that where human use is clearly intended. None of BPC-157, TB-500, LL-37 or KPV is a licensed medicine.
What should a peptide certificate of analysis include?
At minimum: a batch number matching the vial, HPLC purity with the chromatogram, a mass spectrum confirming the molecular mass, and an endotoxin result by USP <85> LAL. Better certificates add net peptide content and the name of an independent laboratory. A CoA lacking a batch number or endotoxin figure is of limited value.
What does 99% purity mean on a peptide CoA?
That 99% of the UV-absorbing peptide material in the HPLC run was the main peak. It does not confirm identity (that needs mass spectrometry), does not measure endotoxin or sterility, and does not mean the vial contains 99% peptide by weight, because bound water and counter-ions typically account for 10–30% of the mass.
Are research peptide vials sterile?
Usually asserted, rarely demonstrated. Licensed injectables are filled aseptically and batch-tested for sterility and endotoxin; retail research vials generally are not. The powder’s sterility cannot be fixed at home. Using a pharmacopoeial-grade diluent such as bacteriostatic water ensures the water is not adding contamination and limits growth during multi-dose use.
References
- The Human Medicines Regulations 2012, Regulation 46: Requirement for authorisation. legislation.gov.uk
- Grey-market peptides: what pharmacists need to know. The Pharmacist, April 2026 (MHRA statements)
- Unauthorized injectable peptide drugs sold by Prime Research may pose serious health risks. Health Canada, April 2025
- 503A Bulk Drug Substances Categories Update, September 29 2023. Alliance for Pharmacy Compounding, 2023
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. US FDA
- FDA Panel Backs 6 Peptides for Compounding. AJMC, July 2026
- Guidance for Industry: Pyrogen and Endotoxins Testing, Questions and Answers. FDA, 2012
- Bacterial Endotoxins/Pyrogens, Inspection Technical Guide. US FDA
- FDA Briefing Document, Pharmacy Compounding Advisory Committee Meeting: BPC-157. US FDA, July 2026
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Bacteriostatic water is supplied for reconstitution of substances intended for research and for use as directed by a healthcare professional. Peptides and medicines discussed here may be unlicensed in the UK or prescription-only; consult a qualified clinician before using any medicine. Baclabs does not sell peptides.